<DOC>
	<DOCNO>NCT00003262</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness two combination chemotherapy regimens treat patient Hodgkin 's disease HIV infection .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Hodgkin 's Disease HIV Infection</brief_title>
	<detailed_description>OBJECTIVES : - Investigate effect survival , life expectancy quality , toxicity , immunological status low risk patient Hodgkin 's Disease HIV infection treat Stanford V regimen high risk patient treat epirubicin , bleomycin , vinblastine , prednisone . OUTLINE : Patients stratify 2 group designate low high risk basis ECOG performance status ( 0-2 v 3-4 ) , presence absence AIDS diagnosis Hodgkin 's Disease , immune status ( CD4+ cell count great v great 100/mm^3 ) . - Low risk patient ( risk factor ) receive EBVP regimen , follow : - Epirubicin intravenously day 1 - Bleomycin intramuscularly intravenously day 1 - Vinblastine intravenously day 1 - Prednisone orally day 1-5 - Patients also receive daily injection filgrastim ( granulocyte colony-stimulating factor ; G-CSF ) day 6-15 . This schedule repeat every 3 week 6 course . - High risk patient ( one risk factor ) receive Stanford V regimen , follow : - Doxorubicin vinblastine intravenously day 1 15 - Mechlorethamine intravenously day 1 - Vincristine bleomycin intravenously day 8 22 - Etoposide intravenously day 15 16 - Prednisone orally daily - Patients also receive daily injection G-CSF day 3-7 , 9-13 , 17-21 , 23-26 . This schedule repeat every 28 day 3 course . Patients follow every 2 month first year every 3 month thereafter . PROJECTED ACCRUAL : 20-30 patient initially accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove Hodgkin 's disease : Clinical pathologic stage II IV Stage I bulky disease ( tumor size great 10 cm ) B symptom Confirmed HIV infection PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 04 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Cardiovascular : No severe cardiac disease Pulmonary : No severe pulmonary disease Other : No severe neurologic metabolic disease No concurrent prior second malignancy except : Nonmelanomatous skin cancer In situ cancer cervix PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No prior therapy Hodgkin 's disease Concurrent tripledrug antiretroviral therapy ( include one protease inhibitor ) require</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2002</verification_date>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>HIV-associated Hodgkin lymphoma</keyword>
</DOC>